Allermi is a technology company.
Allermi has raised $4.0M across 1 funding round.
Key people at Allermi.
Allermi has raised $4.0M in total across 1 funding round.
Key people at Allermi.
Allermi has raised $4.0M in total across 1 funding round.
Allermi's investors include FirstMark Capital, Founder Collective, RET Ventures, Ribbit Capital, Touchdown Ventures, Zigg Capital, Shane Neman.
##
# Allermi
Allermi is a San Francisco-based health-tech startup offering personalized allergy relief through custom prescription nasal sprays. The company serves allergy sufferers, particularly those with nasal symptoms like congestion, runny nose, and sneezing, by providing direct-to-consumer telehealth services. Patients complete an online intake form detailing their medical history and symptoms, which board-certified allergists review to formulate a tailored nasal spray combining up to four active ingredients (e.g., azelastine, ipratropium, triamcinolone, oxymetazoline) at precise dosages, delivered monthly for $45.[1][2][5] Allermi also sells a complementary moisturizing saline nasal mist called Salinity Spray. Over 90% of patients report superior relief compared to prior solutions, driving 30%+ month-over-month growth since its California launch, with availability now in 28 states.[2][5]
Allermi was co-founded by Shani Bocian Steinberg (CEO) and her father, Dr. Robert Bocian, a Stanford University associate professor of allergy and immunology with over 30 years of experience.[2][3] The idea stemmed from Dr. Bocian's earlier innovation, "Bocian's Potions," which combined and customized doses of clinically tested medications into a single nasal spray for specific patient symptoms.[2] Launched in California in July 2022 with a $1.25M pre-seed round led by Lucas Venture Group, Allermi secured a $3.5M seed round in 2023 led by Nelstone Ventures, fueling nationwide expansion.[2][4] Early traction included rapid growth and strong patient satisfaction, positioning it as a telehealth pioneer in compounded allergy care.[1][2]
Allermi rides the telehealth and personalized medicine wave, capitalizing on post-pandemic demand for convenient, at-home care amid rising allergy prevalence. Its timing aligns with regulatory shifts enabling compounded medications and AI-driven efficiencies in healthcare delivery, addressing gaps in over-the-counter remedies that fail chronic sufferers.[3] Market forces like a massive U.S. rhinitis patient base (110M) and preference for targeted therapies favor its direct-to-consumer model, influencing the ecosystem by pioneering customized nasal sprays and inspiring niche health-tech specialization.[2][3] As the first to commercialize such sprays at scale, Allermi sets a blueprint for symptom-specific telehealth, potentially accelerating adoption of precision compounding in other conditions.[1][3]
Allermi's momentum—fueled by proven patient outcomes, funding, and expansion—positions it for national dominance in allergy care, with plans for complementary products like Salinity Spray expansions, strategic partnerships, and AI to streamline operations.[3] Trends like AI personalization and telehealth deregulation will amplify growth, potentially evolving Allermi into a full nasal care platform while maintaining its niche edge. Watch for Series A scaling and broader U.S. coverage, solidifying its role as the go-to for superior, science-backed allergy relief that outpaces generic alternatives.[2][3]
Allermi has raised $4.0M across 1 funding round. Most recently, it raised $4.0M Seed in March 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2023 | $4.0M Seed | FirstMark Capital, Founder Collective, RET Ventures, Ribbit Capital, Touchdown Ventures, Zigg Capital, Shane Neman |
